17 results on '"Quintanilla, L."'
Search Results
2. EP06.08: Influence of prenatal risk factors on the prevalence of preleukemic ETV6: RUNX1 lesions in cord blood.
- Author
-
Quintanilla, L. Benitez, Fischer, U., Crispi, F., Castro‐Barquero, S., Crovetto, F., Sola, M. Larroya, Youssef, L., Castillo, H., Bueno, C., Borras, R., Borkhardt, A., Vieta, E., Estruch, R., Menendez, P., and Gratacos, E.
- Subjects
- *
CORD blood , *MULTIPLE regression analysis , *PRENATAL influences , *GENE fusion , *LOGISTIC regression analysis - Abstract
This article discusses a study that aimed to explore the influence of prenatal risk factors on the prevalence of preleukemic ETV6:RUNX1 fusion gene in cord blood samples. The study analyzed cord blood samples from 1221 pregnancies and found that the prevalence of the fusion gene was 6.5%. Maternal Maghreb ethnicity and prenatal exposure to corticosteroids were identified as potential risk factors for the appearance of the fusion gene. The study suggests that further research is needed to confirm these findings and develop prevention strategies. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
3. OP15.08: Mediterranean diet pattern as a protective factor against pre‐eclampsia.
- Author
-
Sola, M. Larroya, Casas, I., Castro, S., Nakaki, A., Youssef, L., Quintanilla, L. Benitez, Genero, M., Gratacos, E., Crispi, F., and Crovetto, F.
- Subjects
PLACENTAL growth factor ,DIETARY patterns ,MEDITERRANEAN diet ,VASCULAR endothelial growth factors ,PREGNANT women ,ECLAMPSIA - Abstract
This article, titled "Mediterranean diet pattern as a protective factor against pre-eclampsia," explores the relationship between maternal dietary habits and the development of pre-eclampsia. The study, conducted in Barcelona, Spain, found that pregnant women with pre-eclampsia had a lower adherence to the Mediterranean diet compared to those with uncomplicated pregnancies. The study also found that extra virgin olive oil, vegetables, and fruit were associated with a lower risk of developing pre-eclampsia, while saturated fatty acids and ultra-processed food were associated with a higher risk. The consumption of extra virgin olive oil was found to improve the antiangiogenic status in pre-eclamptic women. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
4. OC02.08: *Effect of Mediterranean diet or stress reduction interventions during pregnancy on placental volume and perfusion: IMPACT BCN trial sub‐analysis.
- Author
-
Nakaki, A., Crovetto, F., Casas, I., Crimella, M., Izquierdo, N., Quintanilla, L. Benitez, Sola, M. Larroya, Genero, M., Castro, S., Gratacos, E., Crispi, F., and Youssef, L.
- Subjects
SMALL for gestational age ,HIGH-risk pregnancy ,MEDITERRANEAN diet ,PREGNANT women ,FETAL development - Abstract
A study conducted at a University Hospital in Barcelona, Spain, investigated the effects of a Mediterranean diet (MedDiet) or mindfulness-based stress reduction (MBSR) during pregnancy on placental volume and perfusion in high-risk pregnancies. The study randomly assigned 1221 pregnant women at high risk for small for gestational age (SGA) into three groups: MedDiet, MBSR, or usual care. The results showed that both interventions were associated with a lower prevalence of small placental volume compared to usual care. These findings suggest that structured interventions based on MedDiet or MBSR during pregnancy may have beneficial effects on fetal growth. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
5. OC16.07: Prediction of survival in congenital diaphragmatic hernia fetuses: which method is better using observed/expected total fetal lung volumes?
- Author
-
Corroenne, R., Quintanilla, L. Benitez, Chabolla, L. Delgadillo, Nassr, A., Donepudi, R., Johnson, R.M., Ketwaroo, P., Mehollin‐Ray, A., Munoz, J.L., Buskmiller, C., Belfort, M., and Cortes, M. Sanz
- Subjects
- *
DIAPHRAGMATIC hernia , *LOGISTIC regression analysis , *LUNG volume , *FETAL MRI , *GESTATIONAL age - Abstract
This article discusses a study that aimed to compare different methods of predicting survival in fetuses with congenital diaphragmatic hernia (CDH). The researchers compared the use of observed/expected total fetal lung volume (O/E TFLV) normalized by gestational age (GA) using first trimester Crown-Rump Length (CRL) versus using fetal size determined at the time of MRI. The study found that there were no differences in the prediction of survival using either method. The findings suggest that both methods can be used to predict survival in CDH fetuses. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
6. OC19.07: *Effect of Mediterranean diet intervention during pregnancy on maternal brain: a secondary analysis of the IMPACT BCN randomised clinical trial.
- Author
-
Gomez, Y., Nakaki, A., Castro, S., Casas, I., Genero, M., Youssef, L., Quintanilla, L. Benitez, Crispi, F., Gratacos, E., and Crovetto, F.
- Subjects
PREGNANT women ,THIRD trimester of pregnancy ,MEDITERRANEAN diet ,BRAIN anatomy ,FOOD consumption - Abstract
This article discusses the effects of a Mediterranean diet (MD) intervention during pregnancy on the cortical structure of the maternal brain. The study analyzed data from a randomized clinical trial involving 1221 pregnant women who were allocated into three groups: MD intervention, Mindfulness-Based Stress Reduction program, or usual care. The results showed that women in the MD group had larger surface areas in certain brain regions compared to the usual care group. The study suggests that promoting a MD during pregnancy can have a significant effect on maternal brain structure. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
7. OC02.06: Assessment of placental perfusion and volume with MR IVIM model and correlation with fetoplacental Doppler in late‐onset fetal growth restriction.
- Author
-
Paolucci, S., Nakaki, A., Youssef, L., Quintanilla, L. Benitez, Casas, I., Genero, M., Crispi, F., Gratacos, E., and Crovetto, F.
- Subjects
FETAL growth retardation ,UTERINE artery ,UMBILICAL cord ,FETAL development ,DIFFUSION magnetic resonance imaging - Abstract
This article discusses a study that aimed to assess placental perfusion and volume using magnetic resonance (MR) and Intra-Voxel Incoherent Motion (IVIM) model, and to examine their associations with fetoplacental Doppler in late-onset fetal growth restriction (FGR) pregnancies. The study involved 28 FGR pregnancies and 131 normally grown fetuses. The results showed that placental volumes were significantly reduced in FGR pregnancies compared to controls, and there was a significant correlation between placental volume and birthweight. However, there was no significant correlation between MR IVIM perfusion parameters and placental insufficiency. The authors suggest that larger sample sizes are needed to confirm these findings. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
8. COMPARATIVE EVALUATION OF ENZYME-LINKED IMMUNOSORBENT ASSAY VERSUS A POINT-OF-CARE TECHNIQUE IN THE DETERMINATION OF ADALIMUMAB LEVELS.
- Author
-
Cajade, F., Toja-Camba, F. J., Rodríguez-Martínez, L., Arcía-Quintanilla, L., Tomine, J., Feitosa, C., Zarra-Ferro, I., Acosta, M. Barreiro-De, González-López, J., Mondelo-García, C., and Fernández-Ferreiro, A.
- Published
- 2024
- Full Text
- View/download PDF
9. EVALUATION OF PROSTATIC SPECIFIC ANTIGEN DEPLETION WITH ABIRATERONE AS A PRONOSTATIVE FACTOR FOR SURVIVAL IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER.
- Author
-
Cajade, F., Tourís-Lores, M., Pupla-Bartoll, A., Soto-Baselga, I., Bernárdez-Ferrán, B., Santana-Martínez, S., García-Quintanilla, L., Castro-Balado, A., Mosquera-Torre, A., López-Montero, E., and Zarra-Ferro, I.
- Published
- 2024
- Full Text
- View/download PDF
10. Septo-dentate gyrus cholinergic circuits modulate function and morphogenesis of adult neural stem cells through granule cell intermediaries.
- Author
-
Chen ZK, Quintanilla L, Su Y, Sheehy RN, Simon JM, Luo YJ, Li YD, Chen Z, Asrican B, Tart DS, Farmer WT, Ming GL, Song H, and Song J
- Subjects
- Animals, Mice, Cell Proliferation, Adult Stem Cells metabolism, Adult Stem Cells physiology, Adult Stem Cells cytology, Morphogenesis, Stem Cell Niche physiology, Male, Neural Stem Cells metabolism, Neural Stem Cells cytology, Dentate Gyrus metabolism, Dentate Gyrus cytology, Neurogenesis physiology, Cholinergic Neurons metabolism, Cholinergic Neurons physiology
- Abstract
Cholinergic neurons in the basal forebrain play a crucial role in regulating adult hippocampal neurogenesis (AHN). However, the circuit and molecular mechanisms underlying cholinergic modulation of AHN, especially the initial stages of this process related to the generation of newborn progeny from quiescent radial neural stem cells (rNSCs), remain unclear. Here, we report that stimulation of the cholinergic circuits projected from the diagonal band of Broca (DB) to the dentate gyrus (DG) neurogenic niche promotes proliferation and morphological development of rNSCs, resulting in increased neural stem/progenitor pool and rNSCs with longer radial processes and larger busy heads. Interestingly, DG granule cells (GCs) are required for DB-DG cholinergic circuit-dependent modulation of proliferation and morphogenesis of rNSCs. Furthermore, single-nucleus RNA sequencing of DG reveals cell type-specific transcriptional changes in response to cholinergic circuit stimulation, with GCs (among all the DG niche cells) exhibiting the most extensive transcriptional changes. Our findings shed light on how the DB-DG cholinergic circuits orchestrate the key niche components to support neurogenic function and morphogenesis of rNSCs at the circuit and molecular levels., Competing Interests: Competing interests statement:The authors declare no competing interest.
- Published
- 2024
- Full Text
- View/download PDF
11. Clinical Effectiveness, Safety, and Compliance of Two Compounded Formulations of Tacrolimus Eye Drops: An Open-Label, Sequential Prospective Study.
- Author
-
Puente-Iglesias M, Cuartero-Martínez A, Touriño-Peralba R, Rodríguez-Ares MT, Giráldez MJ, Yebra-Pimentel E, García-Quintanilla L, García-Otero X, González-Barcia M, Zarra-Ferro I, Otero-Espinar FJ, Fernández-Ferreiro A, and Castro-Balado A
- Subjects
- Humans, Female, Male, Prospective Studies, Middle Aged, Adult, Immunosuppressive Agents chemistry, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents therapeutic use, Aged, Drug Compounding, Cyclodextrins chemistry, Treatment Outcome, Intraocular Pressure drug effects, Tacrolimus chemistry, Tacrolimus administration & dosage, Tacrolimus adverse effects, Tacrolimus therapeutic use, Ophthalmic Solutions chemistry
- Abstract
Ophthalmic tacrolimus compounded formulations are usually made from the commercial intravenous presentation, which contains ethanol as a solubilizer due to the low solubility of tacrolimus. The use of cyclodextrins is presented as an alternative to ethanol, an ocular irritant excipient, to avoid its long-term irritant effects. Open-label, sequential, prospective study to compare effectiveness, safety, and adherence of a new formulation of 0.015% tacrolimus with cyclodextrins (TCD) versus 0.03% tacrolimus with ethanol (TE). The ocular evaluation was assessed by ocular signs, corneal staining, subjective questionnaires as Visual Function Questionnaire (VFQ-25) and Visual Analogue Scale (VAS) of symptoms, lacrimal stability, ocular redness, and intraocular pressure. Compliance was assessed by VAS of adherence and empirically (difference between theoretical and actual consumption). Clinical ocular signs and corneal staining score remained stable for most patients 3 months after switching formulations. The TCD formulation did not modify the tear stability and intraocular pressure of the treated patients compared to the TE formulation. TCD eye drops significantly decreased the subjective pain values on VFQ-25 scale and burning sensation on the VAS symptom scale in comparison to TE formulation after 3 months after the change to TCD formulation. The novel tacrolimus in cyclodextrins formulation is a promising alternative for treating inflammatory ocular pathologies refractory to first-line treatments.
- Published
- 2024
- Full Text
- View/download PDF
12. Influence of adiposity and sex on SARS-CoV-2 antibody response in vaccinated university students: A cross-sectional ESFUERSO study.
- Author
-
Perales-Torres AL, Perez-Navarro LM, Garcia-Oropesa EM, Diaz-Badillo A, Martinez-Lopez YE, Rosas M, Castillo O, Ramirez-Quintanilla L, Cervantes J, Sciutto E, Munguia Cisneros CX, Ramirez-Pfeiffer C, Vela L, Tapia B, and Lopez-Alvarenga JC
- Abstract
Prior studies have identified various determinants of differential immune responses to COVID-19. This study focused on the Ig-G anti-RBD marker, analyzing its potential correlations with sex, vaccine type, body fat percentage, metabolic risk, perceived stress, and previous COVID-19 exposure. In this study, data (available in S1 Data) were obtained from 108 participants from the ESFUERSO cohort, who completed questionnaires detailing their COVID-19 experiences and stress levels assessed through the SISCO scale. IgG anti-RBD concentrations were quantified using an ELISA assay developed by UNAM. Multiple regression analysis was employed to control for covariates, including sex, age, body fat percentage, body mass index (BMI), and perceived stress. This sample comprised young individuals (average age of 21.4 years), primarily consisting of females (70%), with a substantial proportion reporting a family history of diabetes, hypertension, or obesity. Most students had received the Moderna or Pfizer vaccines, and 91% displayed a positive anti-RBD response. A noteworthy finding was the interaction between body fat percentage and sex. In males, increased adiposity was associated with decreased Ig-G anti-RBD concentration; in females, the response increased. Importantly, this pattern remained consistent regardless of the vaccine received. No significant associations were observed for dietary habits or perceived stress variables. This research reports the impact of sex and body fat percentage on the immune response through Ig-G anti-RBD levels to COVID-19 vaccines. The implications of these findings offer a foundation for educational initiatives and the formulation of preventive policies aimed at mitigating health disparities., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Perales-Torres et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
13. Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2 & PRN473 reduces venous thrombosis formation in mice.
- Author
-
Smith CW, Campos J, Brown HC, Jooss NJ, Ivanova VS, Harbi M, Garcia Quintanilla L, Jossi S, Perez-Toledo M, Rookes K, Brill A, Theodore LN, Owens T, La Stant JJ, Foulke MC, Mukai S, Francesco M, Storek MJ, Hicks A, Langrish C, Nunn PA, Cunningham AF, Chauhan A, Thomas MR, Watson SP, and Nicolson PLR
- Abstract
Platelet CLEC-2 is a hemITAM-containing receptor which has a critical role in venous thrombosis, but minimal involvement in haemostasis. CLEC-2 can be blocked by Btk inhibitors. Treatment with ibrutinib is associated with increased bleeding due to off-target inhibition of Src family kinases (SFKs). Patients with X-linked agammaglobulinemia (XLA) who lack Btk however do not bleed, suggesting selective Btk inhibition is a viable antithrombotic strategy. We assessed the effects of selective Btk inhibitors PRN1008 (rilzabrutinib) and PRN473 on platelet signalling and function mediated by CLEC-2 and GPVI. We used healthy donor and XLA platelets to determine off-target inhibitor effects. Inferior vena cava (IVC) stenosis and Salmonella infection mouse models were used to assess antithrombotic effects of PRN473 in vivo. PRN1008 and PRN473 potently inhibited CLEC-2-mediated platelet activation to rhodocytin. No off-target inhibition of SFKs was seen. PRN1008 treatment of Btk-deficient platelets resulted in minor additional inhibition of aggregation and tyrosine phosphorylation, likely reflecting inhibition of Tec. No effect on GPCR-mediated platelet function was observed. PRN473 significantly reduced the number of thrombi in podoplanin positive vessels following Salmonella infection and the presence of IVC thrombosis following vein stenosis. The potent inhibition of human platelet CLEC-2, and reduced thrombosis in in vivo models, together with the lack of off-target SFK inhibition and absence of bleeding reported in rilzabrutinib treated immune thrombocytopenia patients, suggest Btk inhibition as a promising antithrombotic strategy., (Copyright © 2024 American Society of Hematology.)
- Published
- 2024
- Full Text
- View/download PDF
14. Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab.
- Author
-
Almuiña-Varela P, García-Quintanilla L, Rodríguez-Cid MJ, Gil-Martínez M, Abraldes MJ, Gómez-Ulla F, Estany-Gestal A, Alcántara-Espinosa JM, Fernández-Rodríguez M, and Fernández-Ferreiro A
- Abstract
Our objective was to evaluate changes in patient-reported outcome measures using the NEI-VFQ 25 questionnaire during a treat and extend regimen in naive neovascular Age-Related Macular Degeneration patients, and its correlation with anatomical and functional data. We conducted a prospective observational study. Patients underwent a treat and extend regimen with intravitreal ranibizumab for neovascular Age-Related Macular Degeneration. Initial response was evaluated at 4th month, and subsequently in every follow-up visit. If a clinical response was achieved, the injection interval was extended in two-week increments, up to a maximum of 12 weeks. Quality of life was assessed using the NEI-VFQ 25 questionnaire at baseline, 4th months, and 12th months. Patients were categorized as good or poor responders based on Best corrected visual acuity, central foveal thickness, intraretinal fluid, or subretinal fluid. Treatment with ranibizumab led to a significant improvement in quality of life, with a mean increase in NEI-VFQ 25 score of 4.27 points in the 12th month. No significant differences in improvement were observed between good and poor responders. Quality of life scores in neovascular Age-Related Macular Degeneration patients improved with intravitreal treatment regardless of the clinical response. The early response following the loading phase could indicate better quality of life after one year of treatment, with Best corrected visual acuity being the clinical parameter with the greatest influence on quality of life.
- Published
- 2024
- Full Text
- View/download PDF
15. The Effect of Systemic Parameters and Baseline Characteristics in Short-Term Response Analysis with Intravitreal Ranibizumab in Treatment-Naive Patients with Neovascular Age-Related Macular Degeneration.
- Author
-
García-Quintanilla L, Almuiña-Varela P, Rodríguez-Cid MJ, Gil-Martínez M, Abraldes MJ, Gómez-Ulla F, González-Barcia M, Mondelo-García C, Estany-Gestal A, Otero-Espinar FJ, Fernández-Rodríguez M, and Fernández-Ferreiro A
- Abstract
Anti-vascular endothelial growth factor drugs keep being the main therapy for neovascular age-related macular degeneration (AMD). Possible predictive parameters (demographic, biochemical and/or inflammatory) could anticipate short-term treatment response with ranibizumab. 46 treatment-naive patients were included in a prospective observational study. They underwent three monthly injections of intravitreal ranibizumab for neovascular AMD and the clinical examination was made at baseline and one month after the third injection. Demographic characteristics, co-morbidities and concomitant treatments were recorded at the baseline visit. Biochemical parameters, complete blood count and inflammation biomarkers were also measured at these times. Uric Acid was found to be statistically significant with a one-point difference between good and poor responders in both basal and treated patients, but only in basal parameters was statistical significance reached ( p = 0.007 vs. p = 0.071 in treated patients). Cholesterol and inflammatory parameters such as white blood cell count and neutrophils were significantly reduced over time when treated with intravitreal ranibizumab. On the other hand, women seemed to have a worse prognosis for short-term response to intravitreal ranibizumab treatment. Uric acid may help identify possible non-responders before initial treatment with ranibizumab, and cholesterol and white blood cells could be good candidates to monitor short-term response to ranibizumab treatment.
- Published
- 2024
- Full Text
- View/download PDF
16. Guidelines for the management of coagulation disorders in patients with cirrhosis.
- Author
-
Aiza-Haddad I, Cisneros-Garza LE, Morales-Gutiérrez O, Malé-Velázquez R, Rizo-Robles MT, Alvarado-Reyes R, Barrientos-Quintanilla LA, Betancourt-Sánchez F, Cerda-Reyes E, Contreras-Omaña R, Dehesa-Violante MB, Flores-García NC, Gómez-Almaguer D, Higuera-de la Tijera MF, Lira-Pedrin MA, Lira-Vera JE, Manzano-Cortés H, Meléndez-Mena DE, Muñoz-Ramírez MR, Pérez-Hernández JL, Ramos-Gómez MV, and Sánchez-Ávila JF
- Subjects
- Humans, Liver Cirrhosis complications, Liver Cirrhosis therapy, Blood Coagulation, Hemostasis, Acute-On-Chronic Liver Failure complications, Blood Coagulation Disorders complications, Blood Coagulation Disorders therapy
- Abstract
Coagulation management in the patient with cirrhosis has undergone a significant transformation since the beginning of this century, with the concept of a rebalancing between procoagulant and anticoagulant factors. The paradigm that patients with cirrhosis have a greater bleeding tendency has changed, as a result of this rebalancing. In addition, it has brought to light the presence of complications related to thrombotic events in this group of patients. These guidelines detail aspects related to pathophysiologic mechanisms that intervene in the maintenance of hemostasis in the patient with cirrhosis, the relevance of portal hypertension, mechanical factors for the development of bleeding, modifications in the hepatic synthesis of coagulation factors, and the changes in the reticuloendothelial system in acute hepatic decompensation and acute-on-chronic liver failure. They address new aspects related to the hemorrhagic complications in patients with cirrhosis, considering the risk for bleeding during diagnostic or therapeutic procedures, as well as the usefulness of different tools for diagnosing coagulation and recommendations on the pharmacologic treatment and blood-product transfusion in the context of hemorrhage. These guidelines also update the knowledge regarding hypercoagulability in the patient with cirrhosis, as well as the efficacy and safety of treatment with the different anticoagulation regimens. Lastly, they provide recommendations on coagulation management in the context of acute-on-chronic liver failure, acute liver decompensation, and specific aspects related to the patient undergoing liver transplantation., (Copyright © 2023 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. Pharmacokinetics of eculizumab in adult and pediatric patients with atypical hemolytic uremic syndrome and C3 glomerulopathy.
- Author
-
Pau Parra A, Ramos N, Perurena-Prieto J, Manrique-Rodríguez S, Climente M, García Quintanilla L, Escolano Á, and Miarons M
- Subjects
- Adult, Humans, Child, Middle Aged, Antibodies, Monoclonal, Humanized therapeutic use, Spain, Atypical Hemolytic Uremic Syndrome drug therapy
- Abstract
Objective: The objective of the study was to analyze and describe the concentrations of eculizumab and the complement blockade in patients with atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy, and to define a therapeutic margin where there is a high probability of achieving therapeutic efficacy., Methods: Observational, ambispective and multicenter study that included adult and pediatric patients diagnosed with aHUS and C3 glomerulopathy from September 2020 to October 2022 in five hospitals in Spain. Eculizumab was administered at the doses recommended by the data sheet according to the European Medicines Agency (EMA). Pre-dose and post-dose concentrations of eculizumab were determined, as well as blockade of the classical complement pathway (CH50). Sociodemographic and clinical data were collected, and pharmacokinetic parameters were calculated. To establish the cut-off point for eculizumab concentrations that predicted complement blockade, Receiver Operating Characteristic (ROC) curve analysis was performed. Lastly, the Kruskal-Wallis test was used to contrast the differences in different parameters according to eculizumab concentrations., Results: Twenty-five patients were included, 19 adults (76.0%) and 6 pediatrics (24.0%), with median ages of 43.4 (IQR 35.7-48.8) and 10.1 (IQR 9.6-11.3) years, respectively. Of these, 22 (88.0%) patients were diagnosed with aHUS and 3 (12.0%) with C3 glomerulopathy. A total of 111 eculizumab concentrations were determined. Mean pre-dose and post-dose concentration values detected during the maintenance phase were 243.8 (SD 240.6) μg/mL and 747.4 (SD 444.3) μg/mL, respectively. Increased complement blockade was observed at higher pre-dose concentrations (p=0.002) and decreased serum creatinine at both higher pre- and post-dose concentrations (p=0.001 and p=0.017, respectively). Using ROC curves, it was determined that a pre-dose concentration >149.0 μg/mL was optimal to achieve complement blockade, with an AUC of 0.87 (0.78-0.95). Finally, high inter-individual (48.9% CV) with low intra-individual variabilities (11.9% CV) in eculizumab clearance were observed., Conclusions: The present study reports supratherapeutic concentrations of eculizumab in patients with aHUS, and defines higher concentrations than those described in the data sheet to achieve blockade, thus encouraging the personalization of treatment with eculizumab., (Copyright © 2023 Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.